2013
DOI: 10.1007/s40265-013-0136-x
|View full text |Cite
|
Sign up to set email alerts
|

Immunosuppression and Allograft Rejection Following Lung Transplantation: Evidence to Date

Abstract: The enduring success of lung transplantation is built on the use of immunosuppressive drugs to stop the immune system from rejecting the newly transplanted lung allograft. Most patients receive a triple-drug maintenance immunosuppressive regimen consisting of a calcineurin inhibitor, an antiproliferative and corticosteroids. Induction therapy with either an antilymphocyte monoclonal or an interleukin-2 receptor antagonist are prescribed by many centres aiming to achieve rapid inhibition of recently activated a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
43
0
3

Year Published

2014
2014
2021
2021

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 45 publications
(46 citation statements)
references
References 221 publications
0
43
0
3
Order By: Relevance
“…T lymphocytes play a pivotal role in the pathogenesis of cell-mediated autoimmune diseases and chronic inflammatory disorders (1)(2)(3). Activation of T lymphocytes requires stimulation of T-cell receptors and costimulatory signals.…”
Section: Introductionmentioning
confidence: 99%
“…T lymphocytes play a pivotal role in the pathogenesis of cell-mediated autoimmune diseases and chronic inflammatory disorders (1)(2)(3). Activation of T lymphocytes requires stimulation of T-cell receptors and costimulatory signals.…”
Section: Introductionmentioning
confidence: 99%
“…27,28 All LTx recipients received standard triple immunosuppression with tacrolimus, azathioprine, or mycophenolate mofetil and corticosteroids. 20 All patients received prophylactic antibiotics based on known or suspected donor and recipient microbiology results. All patients at high risk of CMV reactivation (either donor- or recipient-positive CMV serostatus) received prophylaxis with 2 weeks of intravenous ganciclovir and then oral valganciclovir for a minimum of 5 months.…”
Section: Methodsmentioning
confidence: 99%
“…In the early years of lung transplantation, it was recognized that there were several syndromes of acute and chronic lung dysfunction associated with the pathology of allo‐rejection . In recent times, the purity of these entities are being challenged and further subgroups are emerging that have important prognostic and therapeutic differences (Fig. ).…”
Section: Basic Concepts—the Relevance Of Lung Physiology To a Lung Trmentioning
confidence: 99%